Champions Oncology

Champions Oncology, Inc. is a company based in Hackensack, New Jersey, specializing in research and development solutions for the pharmaceutical industry. With 188 employees, the company generates $46.8 million in annual revenue. Champions Oncology offers a comprehensive range of services that support the oncology drug development process. These include in vitro and in vivo testing platforms, leveraging both commercially available and custom cell lines. Their expertise extends to syngeneic and traditional patient-derived xenograft (PDX) models, as well as evaluating treatment response in clinical settings. A key differentiator for Champions Oncology is its proprietary Champions TumorGraft® (CTG) platform. This comprehensive compendium of PDX models, sourced through a network of renowned oncology institutions and the company's Personalized Oncology Solutions business, accurately reflects the biological characteristics of human tumors and predicts clinical outcomes. Using these models, clients can evaluate tumor sensitivity/resistance to various therapies, identify biomarkers, and discover novel drug combinations. For inquiries or to learn more about Champions Oncology's services, interested parties can visit their website at championsoncology.com.